The following is a summary of “Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy,” published in the March 2025 issue of Journal of the American College of Cardiology by Judge et al. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and underdiagnosed disease characterized by worsening heart failure, diminished quality of […]
The post Acoramidis as a Therapeutic Advance for ATTR-CM first appeared on Physician’s Weekly.
